Scientists discover how to improve immune response to cancer

Apr 26, 2009

A team of scientists at The Campbell Family Institute for Breast Cancer Research (CFIBCR) at Princess Margaret Hospital and international collaborators have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.

The findings, published online today in (DOI: 10.1038/nm.1953), demonstrate the tantalizing potential of in treatment, says principal investigator Dr. Pamela Ohashi, co-director, CFIBCR.

In the lab study, the scientists combined interleukin-7 (IL-7) - a key component of the - with a viral vaccine to improve the ability of the cells of the immune system to attack tumours. The result was clear: The combination boosted immunity to tumours.

"We are extremely excited because our research has revealed the unexpected ways IL-7 works to break down barriers that naturally block the immune response to tumours. This is important because current vaccine approaches for immune therapy induce a response in just 1% to 3% of patients," says Dr. Ohashi, a senior scientist in signaling biology who holds a Canada Research Chair in Autoimmunity and Tumour Immunity. She is also a Professor, University of Toronto, in the Department of Medical Biophysics and Immunology. "

Dr. Tak Mak, co-author and CFIBCR director, says: "The promise of using the body's own defenses to fight cancer is enormous. The day is coming when immunotherapy may help spare cancer patients the toxic side effects of traditional therapies and greatly improve their quality of life while treating the disease. This is why we are planning to expand our immunotherapy research program at PMH." Dr. Mak is also a Professor, University of Toronto, in the Department of Medical Biophysics and Immunology.

This research was also financially supported by grants and fellowships from the Canadian Institute for Health Research, the Ontario Institute for Cancer Research, the Terry Fox Foundation, the National Cancer Institute of Canada, the Boninchi Foundation (Geneva) and the Irvington Institute with the Cancer Research Institute (New York).

Source: University Health Network

Explore further: Survival differences seen for advanced-stage laryngeal cancer

add to favorites email to friend print save as pdf

Related Stories

Scientists discover cancer-causing role of gene proteins

Sep 18, 2008

Dr. Tak Mak and scientists at The Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital have discovered the role of two "cousins" in the genetic family tree of cancer development.

Cancer vaccine may be possibility

Feb 24, 2006

Researchers at the University of Washington and the Fred Hutchinson Cancer Center are working on a vaccine to prevent cancer.

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

13 hours ago

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

22 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

Hospital volume not linked to costs of cancer surgery

Nov 26, 2014

(HealthDay)—Hospital surgical volume does not appear to correlate with Medicare payments for cancer surgery, according to research published online Nov. 24 in the Journal of Clinical Oncology.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.